Klaus Fink, PhD

Head of Neurotoxin and Biotechnology Development
Merz Therapeutics GmbH, Germany

Poster(s):

• 1341 - Effects of IncobotulinumtoxinA in an Animal Model of Trigeminal Pain
  Friday, February 20, 2026

  5:00 PM - 6:30 PM AST